Particulated Juvenile Cartilage Allograft (DeNovo)

Systematic Review Evidence (241 patients, 2024)

→ DeNovo uses tiny cartilage pieces from young donors (under 13). Young cartilage has more "stem cell-like" properties. Mixed with fibrin glue and placed into the defect.

Key Findings

• AOFAS improved from 58.5 to 83.9 [46]
• Most common complication: allograft hypertrophy (13.2%) [46]
• Lesions >125mm² had significantly increased failure risk [46]
• Male sex was a risk factor; age, BMI, prior surgery were NOT [46]

2024-2025 Clinical Updates

Recent studies have provided more data on particulated juvenile cartilage [83]:

• 5-year follow-up shows continued concern about durability
• Tissue quality on MRI remains fibrocartilaginous rather than hyaline
• Newer scaffold-assisted techniques may improve outcomes

11-Year Case Report

Long-term case report with second-look arthroscopy showed graft survival at 11 years [47].

Product Availability Note (2024)

DeNovo NT (natural tissue) is manufactured by Zimmer Biomet. Availability may be limited in some regions, and cost remains significant (~$5,000-8,000 for the graft alone) [84].

Conclusion: High complication and failure rates call into question efficacy for large OLTs. Cannot be currently recommended for lesions >125mm² [46].

Added August 4, 2026 — minced cartilage is now routine in European knees, and that gap is the point

→ A close cousin of this procedure has quietly become standard practice in one joint while the evidence in the ankle has not moved at all.

A survey of all 4,915 members of the German arthroscopy society, published August 3, found that minced cartilage implantation “has emerged as one of the three most commonly used cartilage repair techniques in the knee joint,” with “defect sizes up to 4 cm²… the largest treated group” [350]. 927 surgeons responded, a 19% response rate.

Read this carefully, because it is easy to over-read. The survey is knee only, contains no ankle data, and reports no outcomes whatsoever — it measures what surgeons say they do, not whether it works. It also found the technique is “quite heterogeneous, with some practitioners using a shaver and others manually mincing with a scalpel,” which means “minced cartilage” does not describe one standardised operation even where it is popular.

Why it belongs on this page anyway: it sharpens the asymmetry this page already documents. Particulated and minced cartilage techniques have crossed into everyday knee practice in Europe, while the talar evidence still rests on small series with high failure rates above 125 mm². Popularity in the knee is not evidence for the talus, and if this approach is ever offered here, that distinction is the question to press.

Added August 21, 2026 — a new talar PJCA series, and it is the most positive one on this page

→ Ten young soldiers had DeNovo put into talar lesions. A year and a bit later, the holes had filled in on MRI, pain had mostly gone, and nine of ten were back on full duty. Good news — with the usual caveats about who was studied and for how long.

A military-hospital group reported 10 active-duty service members (all male, mean age 28.4) treated arthroscopically with particulated juvenile cartilage allograft for symptomatic talar osteochondral defects, followed for a median of 15 months [431]. MRI lesion volume fell from 0.77 to 0.02 cm³, MOCART rose from 25 to 75, pain fell from 6 to 1 out of 10, FAAM daily-living scores went from 50% to 87.5% and sports scores from 15% to 85%. Nine of ten returned to full duty; one was medically separated; no complications were reported.

How to weigh it against the rest of this page. The standing conclusion here comes from the 2024 systematic review [46]: high complication and failure rates, and PJCA cannot be recommended for lesions above 125 mm². This new series does not overturn that — it is Level IV, ten patients, under two years, in the fittest possible population (young, male, military), and it reports no lesion-size stratification to test the 125 mm² line. The [46] failures clustered at a mean of roughly two years, which is after this cohort’s follow-up ends. MRI fill and MOCART improvement are also not the same as durable hyaline repair.

Why it matters anyway: it is the first new talar PJCA outcome series since the systematic review, and its numbers are strongly positive in exactly the return-to-activity dimension this site cares about (FAAM sports 15%→85%). If PJCA is ever offered here, this paper will be the one quoted in clinic — and the right response is to ask about lesion size, follow-up beyond two years, and the [46] failure curve, not to dismiss it.

Added September 7, 2026 — an NYU group reviews the whole “cartilage-from-a-vial” class, and its DeNovo verdict matches this page’s

→ Surgeons at NYU read everything published on the three off-the-shelf cartilage allograft products — the class DeNovo belongs to — and their summary is blunt: mixed results, grafts that don’t reliably take, high failure rates, and for the newest product, zero published human studies at all. An independent second opinion that lands where this page already stands.

A scoping review from NYU Langone’s foot-and-ankle division, published online September 7 in Foot & Ankle Specialist, surveys the cartilaginous non-structural allograft class — BioCartilage, DeNovo NT, and CartiMax — as the intermediary rung between failed marrow stimulation and osteochondral transplantation [464]. Its product-level verdicts: BioCartilage “may improve radiographic defect fill” as an adjunct but without consistently superior functional outcomes (topic 4’s standing read); DeNovo NT shows “mixed clinical and radiographic outcomes, including persistent postoperative marrow edema, inconsistent graft incorporation, and relatively high complication and failure rates”; and CartiMax has no published peer-reviewed human clinical outcome studies — only preclinical and industry-supported work. The closing note is about money: with little evidence of long-term functional superiority over marrow stimulation alone, cost-effectiveness is an open question for the entire class.

How to weigh it: Level V by design, a scoping (not systematic) review, no pooled numbers — and it synthesizes primary studies this page already carries ([46], [431]), so it adds a verdict rather than data. Why it earns a section anyway: it is an independent academic group reaching this page’s conclusion from the same literature — and if any of these products is ever proposed for this ankle, “the 2026 NYU review found no consistent functional advantage over marrow stimulation, and CartiMax has no human data” is a one-sentence clinic response with a citation behind it.